A Phase I Trial of Samarium-153-Lexidronam Complex for Treatment of Clinically Nonmetastatic High-Risk Prostate Cancer: First Report of a Completed Study
International Journal of Radiation Oncology*Biology*Physics(2011)
摘要
Conclusions Our trial demonstrates that 2 mCi/kg 153 Sm -EDTMP with HT and RT was safe and feasible in men with high-risk M0 prostate cancer. A Phase II study to test this treatment is currently underway by the Radiation Therapy Oncology Group.
更多查看译文
关键词
Prostate cancer,Hormonal therapy,Radiation therapy,Samarium-153
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要